Quanterix announces proposed public offering of common stock

Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In connection with the offering, Quanterix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price. All of the shares in the offering will be sold by Quanterix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan Securities LLC and SVB Leerink LLC are acting as joint book-running managers for the offering. Canaccord Genuity LLC is acting as co-manager for the offering.

The public offering will be made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by telephone at (800) 808-7525, ext. 6132 or by e-mail at [email protected]. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quanterix. (2019, October 25). Quanterix announces proposed public offering of common stock. News-Medical. Retrieved on September 30, 2023 from https://www.news-medical.net/news/20190807/Quanterix-announces-proposed-public-offering-of-common-stock.aspx.

  • MLA

    Quanterix. "Quanterix announces proposed public offering of common stock". News-Medical. 30 September 2023. <https://www.news-medical.net/news/20190807/Quanterix-announces-proposed-public-offering-of-common-stock.aspx>.

  • Chicago

    Quanterix. "Quanterix announces proposed public offering of common stock". News-Medical. https://www.news-medical.net/news/20190807/Quanterix-announces-proposed-public-offering-of-common-stock.aspx. (accessed September 30, 2023).

  • Harvard

    Quanterix. 2019. Quanterix announces proposed public offering of common stock. News-Medical, viewed 30 September 2023, https://www.news-medical.net/news/20190807/Quanterix-announces-proposed-public-offering-of-common-stock.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference